The REDEFINE 4 trial evaluated weight loss outcomes for CagriSema vs tirzepatide in over 800 adults with obesity through week 84.

Lilly’s amassing of a $1.5bn pre-launch inventory follows sizeable investments into US manufacturing facilities.

The World Health Organization (WHO) has endorsed the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of obesity, despite calling for strategies to expand the drugs’ ...

Find out more about how GLP-1RAs are associated with a reduced risk of aneurysmal rupture in high-risk patient populations.

By Tarun Sai Lomte Widely used weight-loss and diabetes drugs show clear benefits, but emerging evidence clarifies their side effects, rare risks, and what clinicians should monitor long term. Review: ...

Researchers have found in a new study that discontinuation of GLP-1 receptor agonists before or early in pregnancy was linked ...

The rapid rise of adults taking GLP-1RA medications (e.g., Wegovy, Ozempic, Mounjaro) in the U.S. (16 million and counting) and around the world has been accompanied by a slew of the drugs’ proclaimed ...

GLP-1RA drugs may lower risk of deadly subarachnoid haemorrhage strokes in diabetes patients.

(Paris, France, Thursday, 18 September 2025) Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major ...

Compared with monotherapy, finerenone plus empagliflozin was associated with improved kidney outcomes in T2D and CKD regardless of GLP-1RA use. Compared with monotherapy and regardless of prior ...